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MAIN TEXT 1 
 2 
INTRODUCTION 3 
Diseases of the adrenal gland are as important for the general practitioner as for the 4 
endocrine specialist. The high prevalence of some adrenal endocrinopathies, such as adrenal 5 
incidentalomas (1-2% of the population) and primary aldosteronism (6% of hypertensives), 6 
which affect millions of patients, makes adrenal diseases such a relevant health issue. The high 7 
morbidity and mortality of some of the rarer adrenal diseases, i.e. Addison’s disease and 8 
Cushing’s syndrome (Table 1), make early detection and appropriate treatment such a challenge 9 
for the health care system.  10 
 11 
Progress in genomics, transcriptomics and steroidobolomics has advanced our 12 
understanding of adrenal pathologies including primary aldosteronism [1], Cushing’s syndrome 13 
[2], adrenocortical carcinoma [3], and pheochromocytoma [4]. Recent progress has been made 14 
in the pathophysiology of many rare adrenal diseases. Foremost has been the identification of 15 
somatic driver mutations in adrenal cortical neoplasms responsible for the characteristic 16 
endocrine autonomy and limited proliferative activity of these endocrine tumors [1]. The rich 17 
genetic background of neoplasms derived from adrenal and extra-adrenal chromaffin cells is 18 
well established with over 16 germline mutation identified to date, many of these and other 19 
(HIF2a, IDH1 & 2, HRAS) also contributing via somatic driver events [4]. It is within this 20 
horizon that adrenal diseases have become a general topic in research and in clinics. 21 
 22 
THE ADRENAL CORTEX CONFERENCE IN MUNICH 2018 23 
In June 2018, we had the privilege to organize the 18th Adrenal Cortex Conference in Munich. 24 
Since 1984 the Conference on the Adrenal Cortex has provided an exciting combination of 25 
 4 
 
science and resources for basic and clinical scientists. The 2018 conference continued the 26 
tradition of including renowned speakers covering the latest research on adrenal development, 27 
hormone signaling, steroidogenesis, adrenal insufficiency, primary aldosteronism, Cushing’s 28 
syndrome and adrenal cancer. As in previous meetings, the Keith L. Parker Memorial Lecture 29 
was awarded to an international leader for his or her contribution to adrenal research. This 30 
year’s laureate was William E. Rainey, the Jerome W. Conn Professor at the University of 31 
Michigan, Ann Arbor, USA, who presented a lecture on his most recent research on the 32 
molecular pathophysiology of primary aldosteronism. Two hundred scientists from around the 33 
globe participated in this prime event of adrenal research giving the meeting a truly international 34 
flavor. More than 100 investigators including many students and young post-docs presented 35 
their research as posters or oral communications.  36 
 37 
We acknowledge the generous support of the Deutsche Forschungsgemeinschaft, which 38 
enabled us to invite many of the internationally leading researchers in the field. Furthermore, 39 
the present December volume of Experimental and Clinical Endocrinology and Diabetes is 40 
entirely dedicated to reviews covering advances in the field of primary aldosteronism. They are 41 
written by experts in their respective fields and include twelve invited articles summarizing 42 
main topics covered at the symposium. 43 
 44 
Primary aldosteronism (PA) has been identified as the leading endocrine cause of 45 
hypertension in recent years. Although still utterly underdiagnosed in clinical practice recent 46 
data point to a higher detection rate in some countries. PA is easily picked up if screened by 47 
the aldosterone-to-renin ratio. However, there are many factors influencing sensitivity and 48 
specificity of the ratio, an area explored by the review of Schilbach, et al. [5]. Perez-Rivas et 49 
al. [6] cover in their review on familial hyperaldosteronism the most recent genetic findings 50 
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currently leading to a potential reclassification. Although there has been a debate about the 51 
true prevalence, with estimates up to 6% in systematic screening approaches [7], genetically 52 
confirmed familial hyperaldosteronism remains a quite rare entity affecting less than 1% of 53 
diagnosed cases of primary aldosteronism. Usually, affected patients present early in infancy 54 
and have a severe course of the disease. Yang et al. [8] provide an analysis of the outcome of 55 
adrenalectomy in unilateral primary aldosteronism. Based on a recently established expert 56 
consensus of 31 specialists, assessment of outcome has been standardized allowing improved 57 
comparison between cohorts of different geographic and genetic backgrounds [9]. However, 58 
this analysis also demonstrated that a certain percentage of patients have in biochemical terms 59 
persistent hyperaldosteronism, and the underlying pathophysiology is discussed in this 60 
review.  61 
 62 
Two manuscripts review the recent advances in the treatment of malignant adrenal diseases, 63 
namely adrenocortical carcinoma (ACC) and malignant pheochromocytoma/paraganglioma 64 
(PPGL). A major breakthrough in treatment of adrenocortical carcinoma has been the 65 
FIRMACT trial published in 2012 [10] which reported results of a randomized trial 66 
comparing 2 chemotherapeutic regimens in stage IV ACC. As a result of this trial, multiple 67 
second and third line therapies have been evaluated [11] which are reported in the review 68 
article by Megerle et al. [12]. Approximately 10% of all PPGL are malignant, and treatment 69 
options in metastasized disease stages include radioactive treatment options (MIBG, 70 
somatostatin receptor based approaches), classical chemotherapy protocols and targeted 71 
treatment approaches. Nölting et al. [12] provide a comprehensive overview of the most 72 
recent advances in the field, including promising pre-clinical data not yet used in clinical 73 
practice.  74 
 75 
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Erlic and Beuschlein [13] summarize the metabolic alterations found in PPGL, including 76 
impaired glucose homeostasis and lipolysis activation, changes in body weight, fat mass and 77 
distribution. Schreiner et al. cover the highly relevant topic of perioperative management of 78 
adrenal tumors [14]. In clinical practice this area is associated with serious morbidity and 79 
mortality which can be avoided by appropriate management.  80 
 81 
Cushing disease (CD), caused by corticotroph adenomas of the pituitary, is a rare devastating 82 
disease with high clinical burden. Remission by transsphenoidal adenomectomy is achieved in 83 
78% [15], but often metabolic, cardiovascular, musculoskeletal and psychiatric comorbidities 84 
persist after long-term biochemical control. These chronically ill patients show an increased 85 
mortality despite disease remission. According to the review by Stalla et al. [16], 86 
comorbidities should be treated aggressively and life-long surveillance is necessary to identify 87 
tumor recurrence at an early stage. Kamilaris et al. [17] give an excellent overview of genetics 88 
and clinics of primary pigmented nodular adrenal disease, a rare cause of adrenal Cushing’s 89 
syndrome, often associated with additional syndromatic features.  90 
 91 
This special issue also highlights the importance of non-tumorous adrenal diseases with high 92 
morbidity, such as Addison’s disease (AD) and congenital adrenal hyperplasia (CAH). In a 93 
timely review, Barthel et al. [18] reflect upon current treatment standards in AD and 94 
improvements in long-term care. Reisch [19] summarizes the long-term sequelae observed in 95 
patients with CAH. There is a shift from the pediatric focus on management of adrenal crisis 96 
and growth to adult problems, namely reproduction and prevention of long-term 97 
cardiovascular and metabolic consequences of the disease.  98 
 99 
 7 
 
The final manuscript by Di Dalmazi [20] addresses recent progress in adrenal incidentalomas, 100 
a topic which has been covered by a European guideline in 2016 [3]. In clinical practice these 101 
guidelines have proven to be very helpful. However, as in other areas of adrenal research, 102 
many open questions remain and have to be addressed by future studies. 103 
 104 
It is within this context that the recently established clinical research center (CRC), “The 105 
adrenal gland: central relay in health and disease” [21], is well suited to approach clinical 106 
issues and basic research questions. The Deutsche Forschungsgemeinschaft approved funding 107 
for this program with 13 mio € from 2017 to 2021, with the option of a further extension until 108 
2029. The 17 research projects and two central support projects at the University Hospitals of 109 
Dresden, Munich and Würzburg cover a broad spectrum ranging from sepsis research to 110 
Cushing’s syndrome, and adrenal gland organ replacement to rodent models of autoimmune 111 
adrenal disease. Several of its principal investigators of the CRC are authors of reviews of this 112 
special issue. Other authors are close collaborators of the CRC scientists, reflecting its 113 
international outreach. This special issue of Experimental and Clinical Endocrinology and 114 
Diabetes provides the interested reader with an opportunity to understand where we are, and 115 
where our research has to go until the next Adrenal Cortex Conference in 2020. 116 
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Table 1: Incidence and prevalence of adrenal diseases in Europe. N.k., not known; OR, Odds ratio; EH; essential 60 
hypertension; PA, primary aldosteronism; IAH, idiopathic adrenal hyperplasia; CD, Cushing disease; SMR, 61 
standard mortality rate; 62 
 63 
 Annual incidence Prevalence Morbidity Mortality 
Congenital adrenal 
hyperplasia 
1:10.000 – 
1:15.000 
 5.8 crises per 100 
patient-years; 
salt wasting: 
8.8; simple 
virilising: 2.5 
The HR of dying 2.3 
(95% CI, 1.2– 4.3) in 
CAH males and 3.5 
(95% CI, 2.0 – 6.0) in 
CAH females 
compared with 
controls  
 
Addison’s disease 4.5/1000.000 82-144/ 1000.000 6-8 adrenal crisis/ 
100 patients/year 
0.5 deaths/100 patient-
years from adrenal 
crisis 
Primary 
aldosteronism 
n.k. 4-6% of 
hypertensive 
population 
OR for stroke:  4.2; 
OR for mi: 6.5;  
OR for AF: 12.1 
compared to EH  
2 times increased for 
treated PA (IAH) 
Cushing disease 1-3/1000.000 66/1000.000  SMR for all-cause 
mortality in treated 
CD: 1·61  
Incidentally 
detected adrenal 
mass 
n.k. 1-2% of general 
population 
n.k. n.k. 
Adrenocortical 
carcinoma 
0.7 – 2.0/ 
1.000.000 
  Median survival: 3-4 
years, 5-year survival  
60–80% for localized 
tumors, and 10-20% 
for metastatic disease  
 64 
